SCHEMBL6645486

SCHEMBL6645486

CN1CCN(c2cc3cc(Cl)ccc3c(=O)[nH]2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 8/20 0.57
▸ HTR3A P46098 5/20 0.57
▸ APAF1 O14727 1/20 0.47
▸ CDC25B P30305 1/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ SENP8 Q96LD8 1/20 0.47
▸ SENP7 Q9BQF6 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ MAT2A P31153 1/20 0.44
▸ HRH1 P35367 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43
▸ TNKS O95271 1/20 0.42
▸ GPR84 Q9NQS5 1/20 0.42
▸ TUBB4A P04350 1/20 0.42
▸ TUBB P07437 1/20 0.42
▸ TUBA3C P0DPH7 1/20 0.42
▸ TUBA1B P68363 1/20 0.42
▸ TUBA4A P68366 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6644383 0.84 APAF1 (0.48) HRH4HTR3AAPAF1CDC25BCASP3
SCHEMBL2166020 0.80 HRH4 (0.57) HRH4HTR3APOLBMEN1KMT2A
SCHEMBL6644205 0.77 APAF1 (0.43) HRH4HTR3AAPAF1CDC25BCASP3
SCHEMBL6648820 0.77 APAF1 (0.63) HRH4HTR3AAPAF1CDC25BCASP3
SCHEMBL6646046 0.76 HRH4 (0.49) HRH4HTR3APOLBMEN1KMT2A
SCHEMBL6648114 0.76 APAF1 (0.48) HRH4HTR3AAPAF1CDC25BCASP3
SCHEMBL6646683 0.75 TNKS (0.60) HRH4HTR3AAPAF1CDC25BCASP3
SCHEMBL6645619 0.75 PDGFRB (0.47) HRH4HTR3AAPAF1CDC25BCASP3
SCHEMBL6650746 0.75 APAF1 (0.47) HRH4HTR3AAPAF1CDC25BCASP3
SCHEMBL6646122 0.74 APAF1 (0.59) HTR3AAPAF1CDC25BCASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 — — US claimed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 — — EP claimed
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 — — US disclosed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof PARP11, PARP1, CD38 HRH4 2085/4885HTR3A 2987/4885APAF1 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback